Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
211At-OKT10-B10 with Melphalan Conditioning for Multiple Myeloma
NCT04466475Phase 1Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2024
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of astatine At 211 OKT10-B10 in multiple myeloma (MM), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Maximum Tolerated Dose. Planned start Jan 2024; status: withdrawn.
02
Drugs
astatine At 211 OKT10-B10
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04466475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04466475.